Following its continuous partnership with the medical community, Algorithm organized on October 6, 2011 a satellite symposium on Livazo® (pitavastatin) during the 10th PanArab congress of the Lebanese Society of Endocrinology, Diabetes and Lipids. 

More than 100 healthcare physicians attended the talk of Pr. John Chapman, president of the European Atherosclerosis Society and a renowned international expert in the biology of plasma lipoproteins and its relevance to the pathophysiology of atherosclerosis and cardiovascular disease.

Pr. Chapman focused during the lecture on the importance of having treatments targeting all the key atherogenic features, rather than low-density lipoprotein-cholesterol (LDL-C) alone, since atherogenic dyslipidaemia is characterized not only by moderate to marked elevation in LDL-C concentration but with high levels of triglycerides (TG) and low levels of high-density lipoprotein-cholesterol (HDL-C). Livazo® (pitavastatin) is a new potent statin uniquely combining the efficacy in significantly decreasing LDL-C and TG levels, plus significant long-term incremental increase of HDL-C and this with a favorable safety & tolerability profiles suitable for polymedicated patients.